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infection. ConClusions: Introducing QIV into the immunization program of the 
United States would prevent a substantial number of hospitalizations and deaths. 
Moreover, cost-effectiveness was shown to be favorable when a cost-effectiveness 
threshold of US$50,000 is applied.
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objeCtives: Approximately 483 patients in Slovakia are living with HIV, with 68 
new infections in 2013. Raltegravir (RAL) is reimbursed for HIV-1-infected treatment-
naive (TN) and treatment-experienced (TE) patients in Slovakia. The objective of this 
analysis was to determine the cost-effectiveness of dolutegravir (DTG) relative to 
RAL. Methods: This study is based on the Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation model. A microsimulation approach simulates the outcome 
of anti-retroviral therapy by following virological suppression and CD4+ cell count 
throughout patients’ lifetime. Each treatment was assigned its specific efficacy, 
adverse events rates, and cardiovascular risk according to lipid parameters evolu-
tion; and costs and quality of life values were allocated by CD4+ cell count categories 
and attached to specific events. The analysis was performed from payer’s perspec-
tive in Slovak settings. Results: Over a lifetime, in TN patients the estimated total 
costs for the DTG strategy compared with the RAL were lower (220,731€ versus 
222,079€ ). The savings for DTG are mostly associated to the lower drug acquisition 
cost. The life expectancy was similar for the DTG and RAL (31.23 years and 30.82 
years). This translated into 0.057 QALYs. DTG was dominant treatment strategy in 
TN patients. In TE patients, the estimated total costs were slightly higher for the 
DTG strategy compared with the RAL (192,682€ versus 188,059€ ). These additional 
costs for the DTG are related to patients living longer with DTG over RAL (19.16 years 
versus 18.30 years). An increment of 0.275 QALYs for DTG was gained. The ICUR for 
the comparison of DTG and RAL was 16,805 € per QALY, which is below the threshold 
19,320€ defined as the limit at which an intervention would be considered as cost-
effective in Slovakia. ConClusions: At the proposed price and when compared to 
RAL, DTG is dominant in TN patients and cost-effective in TE patients.
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objeCtives: The aim of this exercise is to evaluate the cost-effectiveness of 
rotavirus vaccination when introduced amongst children as part of the National 
Immunization Program of Libya. Methods: We used a published simple decision 
tree model about rotavirus disease and the impact of vaccination. The model has 
been adapted to the Libyan situation for analyzing the cost-effectiveness of the 
vaccine among a birth cohort of 160,000 children followed over an at risk period of 
5 years. The evaluation of diarrhea events in 3 public hospitals helped to estimate 
the burden of rotavirus patients confirmed with lab testing during the period from 
August 2012 to April 2013. The economic analysis was done from 2 perspectives: 
health provider and patient. Uni-variate sensitivity analyses were conducted to 
assess the uncertainty in some of the variables in the model. Results: The evalu-
ation study of the 3 hospitals reported 545 diarrhea patients aged below 5 years 
old amongst whom 311 or 57% were rotavirus positive. The societal cost to treat a 
rotavirus diarrhea event was estimated at US$ 661/event. With the simple model we 
estimated that with a vaccine coverage rate of 98%, the vaccine may avoid 47,000 
rotavirus diarrhea events in the birth cohort over a period of 5 years. The estimated 
cost offset is around US$ 2 million. From a health care perspective including only 
direct medical cost the incremental cost-effectiveness ratio (ICER) with a vaccine 
price of US$ 27 per course was US$ 8,972 per QALY gained. This result is below 
the Libyan Gross Domestic Product (GDP) per capita of US$ 10,132. From a societal 
perspective the analysis shows cost savings of around US$ 16 per child in the birth 
cohort. ConClusions: The economic model shows that rotavirus vaccination 
could be an economically attractive intervention for Libya when compared with 
no vaccination.
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objeCtives: The presented economic model estimates costs and benefits of a 
new in vitro diagnostic kit for infective endocarditis (IE), developed by Hutman 
Diagnostics AG (Basel, Switzerland). The product applies molecular diagnos-
tics to detect bacteria in cardiac tissue. In order to assess the potential financial 
and economic performance of the novel kit as compared to standard micro-
biological cultures (MC), a health economic study for Switzerland has been con-
ducted. Methods: As the kit provides results within 4-6 hours after sampling 
instead of 2-3 days by MCs, three outcome scenarios for aetiopathology of IE were 
investigated by establishing a decision tree and potential economic savings were 
examined. The outcome spectra and their economic performance were assessed 
for both diagnostic methods. The first scenario includes decreased hospitalisation 
and earlier specific antibiotic treatment due to quicker diagnosis. The second sce-
nario focuses on the avoidance of reoperation, while the third scenario includes 
the mitigation of mortality. The quantitative model uses statistical data obtained 
from literature and interviews with clinical experts. Parameters quantified were e. g. 
capital and labour costs, costs for antibiotic treatment and productivity losses. 
objeCtives: To evaluate the cost-effectiveness of a new generation integrase 
inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and 
INI-naïve HIV adults with at least two- classes resistance, compared to raltegravir 
(RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation (ARAMIS) model. Methods: ARAMIS is a microsimula-
tion model using 500,000 simulations with a lifetime analytic time horizon and a 
monthly cycle length. Markov health states were defined by HIV health state (with 
or without opportunistic infection). The initial cohort, efficacy and safety data 
of the model were derived from SAILING, a phase III pivotal study. Antiretroviral 
treatment (ART) algorithms were based on French guidelines (2013) and experts 
opinion according to patients’ treatment history, including INI resistance status. 
Costs were mainly derived from the study by Sloan et al. (2012), which included 
routine HIV and opportunistic infection care, and death. Results: The ARAMIS 
model indicates that DTG compared to RAL over a life time is associated with 
additional quality-adjusted life years (QALY; 10.751 versus 10.406, 0.345 difference) 
and additional costs (€ 391,273 versus € 385,568, € 5,705 difference). DTG increased 
costs are mainly related to a 9.1-month increase in life expectancy for DTG com-
pared with RAL, and consequently a longer time spent on ART. The incremental 
cost-effectiveness ratio (ICER) for DTG compared with RAL is € 16,526 per QALY and 
€ 15,341 per life year. About 83% and 14% of total lifetime costs were associated 
with ART and routine HIV care respectively. Univariate deterministic sensitiv-
ity analyses demonstrated the robustness of the model with ICER varying from 
€ 11,038 to € 48,197 per QALY. ConClusions: DTG is a cost-effective strategy in the 
management of TE patients in France considering a collective perspective. These 
results are mainly explained by the superior efficacy of DTG reported in SAILING 
and its higher genetic barrier to resistance relative to RAL.
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objeCtives: In 2012, NICE recommended protease inhibitors as first line treat-
ment for G1 HCV infection. The objective of the analysis was to assess the cost-
utility of SMV/PR versus recommended comparator regimens used to treat G1 and 
G4 patients in the NHS. Methods: The model involved a treatment phase fol-
lowed by a post-treatment Markov phase, capturing lifetime outcomes according 
to whether sustained virologic response (SVR) had been achieved. SMV/PR was 
compared with PR, telaprevir + PR (TVR/PR), and boceprevir + PR (BOC/PR) in G1 
treatment-naïve and treatment-experienced patients. In G4, SMV/PR was compared 
with PR. Dosage regimens, including response-guided therapy and futility stopping 
rules, were based on the EMA approved labels. G1 SVR estimates were derived from 
a mixed treatment comparison; a matching-adjusted indirect comparison was used 
for G4. Patient baseline characteristics were drawn from a UK HCV dataset analy-
sis and clinician opinion. Health state transition probabilities, utilities and health 
state costs were drawn from published UK analyses. Sensitivity analyses were con-
ducted to assess uncertainty around estimated costs and quality-adjusted life years 
(QALY). Results: The G1 model yielded an ICER for SMV/PR vs PR of £14,206/QALY 
for treatment-naïve and £9,793/QALY for treatment-experienced patients. SMV/PR 
dominated TVR/PR and BOC/PR in both patient groups. In G4, the ICER for SMV/PR 
vs PR was £20,791/QALY and £11,662/QALY for treatment-naïve patients using the 
two most appropriate studies for matching. The ICER was £12,070/QALY and £8,896/
QALY for treatment-experienced patients. In both models, multivariate probabilistic 
sensitivity analysis revealed that at a willingness to pay of £20,000/QALY, SMV/PR 
had the highest probability of being the most cost effective intervention, regardless 
of treatment experience. Results were robust to univariate and scenario sensitivity 
analyses. ConClusions: Compared to other regimens currently available within 
the NHS, SMV/PR is a cost-effective option to treat G1 and G4 HCV patients, regard-
less of treatment experience.
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bACKGRound: Currently used trivalent influenza vaccines (TIVs) contain two 
strains of influenza A and one strain of influenza B. However, co-circulation of two 
distinct B lineages and difficulties in predicting which lineage will predominate 
in the next season have led to frequent B-strain mismatches. Newly registered 
quadrivalent influenza vaccines (QIVs) include two B strains and might therefore 
provide wider protection. objeCtives: To evaluate the cost-effectiveness of using 
QIV versus TIV for routine influenza vaccination in the United States (US) during 
the next 20 years. Methods: A dynamic transmission model was used to estimate 
the additional protection offered by QIV over TIV against symptomatic influenza 
B disease. Subsequently, we used a decision tree model to determine the cost-
effectiveness of replacing TIV with QIV from a societal perspective. US data on 
influenza-related disease outcomes and corresponding costs were derived from 
published sources (e. g. Molinari et al. 2007). Results: Over 20 years, replacing TIV 
with QIV is predicted to prevent 13.3 million influenza B cases. According to our 
model this resulted in a reduction of 113,000 hospitalizations and 13,200 deaths. 
Moreover, 200,000 quality- adjusted life-years (QALYs), US$3.1 billion in medical 
costs and US$0.6 billion in indirect costs were saved. The base case estimate of 
the incremental cost-effectiveness ratio (ICER) was US$29,000 per QALY gained. 
Economic parameters with highest impact on the ICER were vaccine price, QALY 
loss due to influenza and probability of hospitalization or death given symptomatic 
